Last reviewed · How we verify
Active Comparator Control 2
Active Comparator Control 2 is a drug that acts as a control in clinical trials.
Active Comparator Control 2 is a drug that acts as a control in clinical trials. Used for Phase 3 clinical trials.
At a glance
| Generic name | Active Comparator Control 2 |
|---|---|
| Also known as | HLIM Placebo+SA160021 Placebo+SA160022 |
| Sponsor | SamA Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
It is used to compare the efficacy and safety of new treatments by serving as a standard against which the new treatments are measured.
Approved indications
- Phase 3 clinical trials
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- The Effects of Commercially Available High Protein Drink on Amino Acid Bioavailability and Recovery From Muscle Fatiguing Exercise in 18-45-year-old Male and Female Participants. (NA)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Examining the Effectiveness of Exercise Training After Cervical Laminoplasty Surgery (NA)
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder (PHASE2)
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
- Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia (NA)
- Phase I PK and Safety Study of Ondansetron Inhalation Powder (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active Comparator Control 2 CI brief — competitive landscape report
- Active Comparator Control 2 updates RSS · CI watch RSS
- SamA Pharmaceutical Co., Ltd portfolio CI